

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

ALLERGAN SALES, LLC and
ALLERGAN, INC.

Plaintiffs,

v.

SANDOZ, INC. and ALCON
LABORATORIES, INC.

Defendants.

Civil Action No. 2:17-cv-10129
CCC-MF

**STIPULATION AND ORDER AMENDING PRETRIAL SCHEDULING ORDER (D.E.
213) AND TO BIFURCATE AND STAY DISCOVERY AND TRIAL
OF DEFENDANTS' ANTITRUST COUNTERCLAIMS**

This stipulation is made by and between Plaintiffs Allergan Sales, LLC and Allergan, Inc. (collectively, "Plaintiffs") and Defendants Sandoz, Inc. and Alcon Laboratories, Inc. (collectively, "Defendants") (Plaintiffs and Defendants collectively referred to as "the parties").

WHEREAS, on April 17, 2018, Defendants filed an Amended Answer to Plaintiffs' Complaint, which included Affirmative Defenses and Counterclaims (Counts 1–18). (D.E. 73);

WHEREAS, on May 22, 2018, Plaintiffs filed their Motion to Dismiss Defendants' Inequitable Conduct and Antitrust Counterclaims and to Strike Defendants' Tenth Affirmative Defense, or Alternatively to Bifurcate and Stay Defendants' Antitrust Counterclaims (D.E. 112), which Motion remains pending;

WHEREAS, this case was stayed on October 29, 2018 (D.E. 189) pending an interlocutory appeal of this Court's order regarding claim construction, and granting Plaintiffs' motion for a preliminary injunction (D.E. 154);

WHEREAS, the mandate from the Federal Circuit's affirmance of this Court's claim construction and preliminary injunction order issued on October 7, 2019 (D.E. 197);

WHEREAS, on January 8, 2020, the Court entered a Pretrial Scheduling Order (D.E. 213);

WHEREAS, the parties agree that an extension of certain deadlines is appropriate, particularly in light of COVID-19, to permit the parties to complete discovery;

WHEREAS, good cause exists to modify the Pretrial Scheduling Order;

WHEREAS, the parties have further agreed that, to promote efficiency for both the parties and the Court, Defendants' Counterclaims Counts 15–18 (together, the "Antitrust Counterclaims") should be bifurcated and stayed from the other claims and defenses at issue in the above-captioned action, and depending on the resolution of those other claims and defenses, one or more or all of the Antitrust Counterclaims shall be dismissed or remain subject to additional or renewed motion practice before the stay is lifted as set out below;

NOW THEREFORE, the parties, by and through their respective undersigned counsel, and subject to the approval of the Court, stipulate and agree as follows:

1. The Antitrust Counterclaims (Counts 15–18) shall be bifurcated from the other claims and defenses at issue in the case (referred to as the "Patent Claims and Defenses"). Discovery and trial unique to the Antitrust Counterclaims (Counts 15–18) shall be stayed until after the Patent Claims and Defenses have been adjudicated to finality. For purposes of this Stipulation and Order, adjudication will be considered final upon the conclusion of any appeals on behalf of Plaintiffs or Defendants to this Court's ruling on the Patent Claims and Defenses.

2. If Plaintiffs prevail on any of the Patent Claims, Defendants will dismiss their Antitrust Counterclaims with prejudice. For the purposes of this Stipulation, Plaintiffs will prevail if any one of the asserted Patent Claims is found infringed and not invalid and/or unenforceable.

3. If Plaintiffs prevail on Defendants' counterclaims related to inequitable conduct, then Defendants will dismiss their Fifteenth Counterclaim for Walker Process Fraud with prejudice. For the purposes of this Stipulation, Plaintiffs will prevail on inequitable conduct if any one asserted Patent Claim is found not unenforceable, even if Defendants are successful in proving non-infringement or invalidity of that claim.

4. Nothing in this Stipulation, however, precludes Plaintiffs from arguing for dismissal of Defendants' Antitrust Counterclaims even if Plaintiffs do not prevail on their Patent Claims.

5. If discovery on the Antitrust Counterclaims should need to resume following final adjudication of the Patent Claims and Defenses, that discovery will continue from where the parties have left off as of the date of this Stipulation. All of the limits on written discovery and depositions that are currently in place will continue to apply. The deadline to serve written discovery has already expired, and the parties will not seek to serve additional written discovery on the Antitrust Counterclaims.

6. The Court's Pretrial Scheduling Order (D.E. 213) is amended as follows. The following dates apply only to the Patent Claims and Defenses, and not to the Antitrust Counterclaims, which are bifurcated and stayed:

Event	Original Deadline	Proposed Deadline
Fact Discovery Closes	May 1, 2020	August 14, 2020
Opening Expert Reports	June 3, 2020	September 16, 2020
Rebuttal Expert Reports	July 1, 2020	October 29, 2020
Reply Expert Reports		November 19, 2020
Expert Discovery Closes	August 1, 2020	December 18, 2020
Pretrial Conference	Q1 2021	Q1 2021
Trial	Q2 2021	Q2 2021

7. The parties otherwise reserve all of their rights, claims, and defenses.

Dated: May 1, 2020

Respectfully submitted,

By: s/Eric I. Abraham
Eric I. Abraham
eabraham@hillwallack.com
HILL WALLACK LLP
21 Roszel Road
Princeton, NJ 08540
Tel: (609) 924-0808

By: s/Liza M. Walsh
Liza M. Walsh
lwalsh@thewalshfirm.com
Eleonore Ofosu-Antwi
eofosuanti@thewalshfirm.com
WALSH PIZZI O'REILLY FALANGA
LLP
Three Gateway Center
100 Mulberry Street, 15th Floor
Newark, NJ 07102
Telephone: (973) 757-1100
Facsimile: (973) 757-1090

Of Counsel:

Bryan Hales
bhales@kirkland.com
Alyse Wu
alyse.wu@kirkland.com
Kyle M. Kantarek
kyle.kantarek@kirkland.com
KIRKLAND & ELLIS LLP
300 North LaSalle
Chicago, IL 60654
Tel: (312) 862 2119

Of Counsel:

Jonathan E. Singer
singer@fr.com
FISH & RICHARDSON P.C.
12390 El Camino Real
San Diego, CA 92130
Tel.: (858) 678-5070

Sean M. McEldowney (*pro hac vice*)
smceldowney@kirkland.com
KIRKLAND & ELLIS LLP
655 Fifteenth Street, N.W.
Washington, D.C. 20005 5793
Telephone: (202) 879 5000

Susan E. Morrison
morrison@fr.com
Douglas McCann
dmccann@fr.com
Robert M. Oakes
oakes@fr.com
FISH & RICHARDSON P.C.
222 Delaware Avenue, 17th Floor
P.O. Box 1114
Wilmington, DE 19899-1114
Tel.: (302) 652-5070

*Attorneys for Defendants and
Counterclaim-Plaintiffs Sandoz Inc. and
Alcon Laboratories, Inc.*

Deanna J. Reichel
reichel@fr.com
FISH & RICHARDSON P.C.
60 S. 6th Street, Suite 3200
Minneapolis, MN 55402
Tel.: (612) 335-5070

Eric S. Hochstadt
eric.hochstadt@weil.com

Lisa Madalone
lisa.madalone@weil.com
WEIL, GOTSHAL & MANGES LP
767 Fifth Avenue
New York, NY 10153
Tel: (212) 310-8000

*Attorneys for Plaintiffs Allergan Sales,
LLC and Allergan, Inc.*

SO ORDERED this 4 day of May, 2020.

A handwritten signature in black ink, appearing to read "Mark Falk", is positioned above a horizontal line.

Hon. Mark Falk, U.S.M.J.